Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.
CancerNetwork® sat down with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, to discuss educational sessions at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Transcript:
I really liked the educational sessions. It’s hard to listen to all the seminars and lectures and but I was able to listen to some of the on-demand sessions. One of those was in targeting DNA-damage repair pathways and immunotherapies, and I thought those were very helpful. I designed trials and see patients [and I] always want to be able to develop trials looking at the most cutting-edge research. We should be able to [do this], we are aiming at [what] translates to the clinic.
![A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ff5ef402e3456a83ca4765506f26761d323734d14-446x339.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.")
